Intellia Therapeutics, Inc. - stock earnings
NTLA Upcoming estimated earnings
| Date | Actual / Estimated EPS | Low Revenue | Actual / Estimated Revenue | High Revenue |
|---|---|---|---|---|
| May 2, 2024 AfterMarket | - / -1.4071000000 | - | - / 11.7 million | - |
NTLA Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023Q4 | -132.2 million USD | -1.9 million USD |
| 2023Q3 | -122.2 million USD | 12.0 million USD |
| 2023Q2 | -123.7 million USD | 13.6 million USD |
| 2023Q1 | -92.3 million USD | 12.6 million USD |
| 2022Q4 | -116.7 million USD | 13.6 million USD |
| 2022Q3 | -111.3 million USD | 13.3 million USD |
| 2022Q2 | -100.0 million USD | 14.0 million USD |
| 2022Q1 | -146.9 million USD | 11.3 million USD |
| 2021Q4 | -81.2 million USD | 12.9 million USD |
| 2021Q3 | -71.6 million USD | 7.2 million USD |
| 2021Q2 | -68.8 million USD | 6.6 million USD |
| 2021Q1 | -46.2 million USD | 6.4 million USD |
| 2020Q4 | -42.2 million USD | 6.6 million USD |
| 2020Q3 | -27.8 million USD | 22.2 million USD |
| 2020Q2 | -32.4 million USD | 16.3 million USD |
| 2020Q1 | -31.8 million USD | 12.9 million USD |
| 2019Q4 | -28.3 million USD | 10.9 million USD |
| 2019Q3 | -23.6 million USD | 10.6 million USD |
| 2019Q2 | -25.7 million USD | 11.1 million USD |
| 2019Q1 | -21.9 million USD | 10.4 million USD |
| 2018Q4 | -19.1 million USD | 7.9 million USD |
| 2018Q3 | -22.7 million USD | 7.4 million USD |
| 2018Q2 | -22.2 million USD | 7.7 million USD |
| 2018Q1 | -21.4 million USD | 7.5 million USD |
| 2017Q4 | -24.0 million USD | 6.7 million USD |
| 2017Q3 | -15.4 million USD | 7.3 million USD |
| 2017Q2 | -15.6 million USD | 5.9 million USD |
| 2017Q1 | -12.6 million USD | 6.2 million USD |
| 2016Q4 | -10.6 million USD | 5.6 million USD |
| 2016Q3 | -7.5 million USD | 4.9 million USD |
| 2016Q2 | -6.9 million USD | 4.2 million USD |
| 2016Q1 | -6.7 million USD | 1.8 million USD |
| 2015Q4 | -5.2 million USD | 1.7 million USD |
| 2015Q3 | -3.0 million USD | 1.7 million USD |
| 2015Q2 | -3.0 million USD | 1.4 million USD |
| 2015Q1 | -1.1 million USD | 1.3 million USD |
| 2014Q4 | -14.3 million USD | ? USD |
NTLA Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -481.2 million USD | 36.3 million USD |
| 2022 | -490.2 million USD | 52.1 million USD |
| 2021 | -259.7 million USD | 33.1 million USD |
| 2020 | -125.6 million USD | 58.0 million USD |
| 2019 | -92.7 million USD | 43.1 million USD |
| 2018 | -85.3 million USD | 30.4 million USD |
| 2017 | -67.5 million USD | 26.1 million USD |
| 2016 | -31.6 million USD | 16.5 million USD |
| 2015 | -12.4 million USD | 6.0 million USD |
| 2014 | -14.3 million USD | ? USD |
NTLA
Price: $22.50
52 week price:
Earnings Per Share: -5.42 USD
P/E Ratio: -5.29
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 1.1 million
Ebitda: -15.1 millionMarket Capitalization: 2.4 billion